BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 20183912)

  • 1. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
    Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
    Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
    Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
    Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
    Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.
    Grossmith S; Nguyen A; Hu J; Plichta JK; Nakhlis F; Cutone L; Dominici L; Golshan M; Duggan M; Carter K; Rhei E; Barbie T; Calvillo K; Nimbkar S; Bellon J; Wong J; Punglia R; Barry W; King TA
    Ann Surg Oncol; 2018 Nov; 25(12):3527-3534. PubMed ID: 29868979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
    Fan YG; Tan YY; Wu CT; Treseler P; Lu Y; Chan CW; Hwang S; Ewing C; Esserman L; Morita E; Leong SP
    Ann Surg Oncol; 2005 Sep; 12(9):705-11. PubMed ID: 16079953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axillary node staging for microinvasive breast cancer: is it justified?
    Lyons JM; Stempel M; Van Zee KJ; Cody HS
    Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
    Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
    J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study.
    Veronesi U; Paganelli G; Viale G; Luini A; Zurrida S; Galimberti V; Intra M; Veronesi P; Maisonneuve P; Gatti G; Mazzarol G; De Cicco C; Manfredi G; Fernández JR
    Lancet Oncol; 2006 Dec; 7(12):983-90. PubMed ID: 17138219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.
    Naik AM; Fey J; Gemignani M; Heerdt A; Montgomery L; Petrek J; Port E; Sacchini V; Sclafani L; VanZee K; Wagman R; Borgen PI; Cody HS
    Ann Surg; 2004 Sep; 240(3):462-8; discussion 468-71. PubMed ID: 15319717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy.
    Rydén L; Chebil G; Sjöström L; Pawlowski R; Jönsson PE
    Eur J Surg Oncol; 2007 Feb; 33(1):33-8. PubMed ID: 17174513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection?-Single-center analysis.
    Nowikiewicz T; Zegarski W; Pagacz K; Nowacki M; Morawiec-Sztandera A; Głowacka-Mrotek I; Sowa M; Biedka M; Kołacińska A
    Breast J; 2018 Sep; 24(5):724-729. PubMed ID: 29476570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection.
    Madekivi V; Boström P; Aaltonen R; Vahlberg T; Salminen E
    Anticancer Res; 2017 Jul; 37(7):3757-3762. PubMed ID: 28668871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of sentinel node re-mapping in patients who have second or recurrent breast cancer and had previous axillary procedures.
    Tokmak H; Kaban K; Muslumanoglu M; Demirel M; Aktan S
    World J Surg Oncol; 2014 Jul; 12():205. PubMed ID: 25016393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.